-
1
-
-
0342952508
-
Pyrimidine and purine antimetabolites
-
(J. F. Holland, R. C. Bast, D. L. Morton, E. Frei III, D. W. Kufe, R.R. Weichselbaum, Eds.), 4th ed., Williams & Wilkins, Baltimore
-
G. Pizzorno, Y. C. Cheng, R. E. Handschumacher, Pyrimidine and purine antimetabolites, in "Cancer Medicine" (J. F. Holland, R. C. Bast, D. L. Morton, E. Frei III, D. W. Kufe, R.R. Weichselbaum, Eds.), 4th ed., pp. 923-948, Williams & Wilkins, Baltimore, 1997.
-
(1997)
Cancer Medicine
, pp. 923-948
-
-
Pizzorno, G.1
Cheng, Y.C.2
Handschumacher, R.E.3
-
2
-
-
0005595182
-
Biochemical modulation: Perspectives and objectives
-
Academic Press, New York
-
D. S. Martin, Biochemical modulation: perspectives and objectives, in "New Avenues in Developmental Cancer Chemotherapy," Academic Press, New York, 1987.
-
(1987)
New Avenues in Developmental Cancer Chemotherapy
-
-
Martin, D.S.1
-
3
-
-
0025815823
-
Clinical relevance of biochemical modulation of 5-fluorouracil
-
G. J. Peters, C. J. van Groeningen, Clinical relevance of biochemical modulation of 5-fluorouracil. Ann. Oncol. 2, 469-480 (1991).
-
(1991)
Ann. Oncol.
, vol.2
, pp. 469-480
-
-
Peters, G.J.1
Van Groeningen, C.J.2
-
4
-
-
0021247086
-
Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: Attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate
-
N. E. Kemeny, T. Ahmed, R. A. Michaelson, Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate. J. Clin. Oncol. 2, 311-315 (1984).
-
(1984)
J. Clin. Oncol.
, vol.2
, pp. 311-315
-
-
Kemeny, N.E.1
Ahmed, T.2
Michaelson, R.A.3
-
5
-
-
0026100241
-
The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer
-
J. C. Marsh, J. R. Bertino, K. H. Katz, C. A. Davis, H. J. Durivage, L. S. Rome, F. Richards, R. L. Capizzi, L. R. Farber, D. N Pasquale, R. Stuart, A. J. Koletsky, R. Makuch, K. O'Hallaren, The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J. Clin. Oncol. 9, 371-380 (1990).
-
(1990)
J. Clin. Oncol.
, vol.9
, pp. 371-380
-
-
Marsh, J.C.1
Bertino, J.R.2
Katz, K.H.3
Davis, C.A.4
Durivage, H.J.5
Rome, L.S.6
Richards, F.7
Capizzi, R.L.8
Farber, L.R.9
Pasquale, D.N.10
Stuart, R.11
Koletsky, A.J.12
Makuch, R.13
O'Hallaren, K.14
-
6
-
-
0024385167
-
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomizsd phase III trial
-
N. Petrelli, H. O. Douglass. Jr., L. Herrera, D. Russell, D. M. Stablein, H. W. Bruckner, R. J. Mayer, R. Schinella, M. D. Green. F. M. Muggia, A. Megibow, E. S. Greenwald, R. M. Bukowski, J. Harris, B. Levin, E. Gaynor, A. Loutfi, M. H. Kaiser, J. S. Barkin, P. Benedetto, P. V. Woolley, R. Nauta, D. W. Weaver, L. P. Leichman, The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomizsd phase III trial. J. Clin. Oncol. 7, 1419-1426 (1989).
-
(1989)
J. Clin. Oncol.
, vol.7
, pp. 1419-1426
-
-
Petrelli, N.1
Douglass Jr., H.O.2
Herrera, L.3
Russell, D.4
Stablein, D.M.5
Bruckner, H.W.6
Mayer, R.J.7
Schinella, R.8
Green, M.D.9
Muggia, F.M.10
Megibow, A.11
Greenwald, E.S.12
Bukowski, R.M.13
Harris, J.14
Levin, B.15
Gaynor, E.16
Loutfi, A.17
Kaiser, M.H.18
Barkin, J.S.19
Benedetto, P.20
Woolley, P.V.21
Nauta, R.22
Weaver, D.W.23
Leichman, L.P.24
more..
-
7
-
-
0025261244
-
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy
-
J. H. Doroshow, P. Multhauf, L. Leong, K. Margolin, T. Litchfield, S. Akman, B. Carr, M. Bertrand, D. Goldberg, D. Blayney, O. Odujinrin, R. Delap, J. Shuster, E. Newman, Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J. Clin. Oncol. 8, 491-501 (1990).
-
(1990)
J. Clin. Oncol.
, vol.8
, pp. 491-501
-
-
Doroshow, J.H.1
Multhauf, P.2
Leong, L.3
Margolin, K.4
Litchfield, T.5
Akman, S.6
Carr, B.7
Bertrand, M.8
Goldberg, D.9
Blayney, D.10
Odujinrin, O.11
Delap, R.12
Shuster, J.13
Newman, E.14
-
8
-
-
0020621335
-
Therapeutic utility of utilizing low doses of N-(phosphonoacetyl)-L-aspartic acid in combination with 5-fluorouracil: A murine study with clinical relevance
-
D. S. Martin, R. L. Stolfi, R. C. Sawyer, S. Spiegelman, E. S. Casper, C. W. Young, Therapeutic utility of utilizing low doses of N-(phosphonoacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance. Cancer Res. 43, 2317-2311 (1983).
-
(1983)
Cancer Res.
, vol.43
, pp. 2317-12311
-
-
Martin, D.S.1
Stolfi, R.L.2
Sawyer, R.C.3
Spiegelman, S.4
Casper, E.S.5
Young, C.W.6
-
9
-
-
0023917467
-
A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonoacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers
-
B, Ardalan, G. Singh, H. Silberman, A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonoacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J. Clin. Oncol. 6, 1053-1058 (1988).
-
(1988)
J. Clin. Oncol.
, vol.6
, pp. 1053-1058
-
-
Ardalan, B.1
Singh, G.2
Silberman, H.3
-
10
-
-
0024992069
-
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer
-
P. J. O'Dwyer, A. R. Paul, J. Walczak, L. M. Weiner, S. Litwin, R. L. Comis, Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J. Clin. Oncol. 8, 1497-1503 (1990).
-
(1990)
J. Clin. Oncol.
, vol.8
, pp. 1497-1503
-
-
O'Dwyer, P.J.1
Paul, A.R.2
Walczak, J.3
Weiner, L.M.4
Litwin, S.5
Comis, R.L.6
-
11
-
-
0026741667
-
Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools
-
G. Pizzorno, R. A. Wiegand, S. K. Lentz, R. E. Handschumacher, Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools. Cancer Res. 52, 1660-1665 (1992).
-
(1992)
Cancer Res.
, vol.52
, pp. 1660-1665
-
-
Pizzorno, G.1
Wiegand, R.A.2
Lentz, S.K.3
Handschumacher, R.E.4
-
12
-
-
0029118868
-
Biochemical modulation of 5-fluorouracil with brequinar: Results of a phase I-II study
-
A. Buzaid, G. Pizzorno, J. C. Marsh, T. S. Ravikumar, J. R. Murren, M. Todd, R. K. Strair, W.-J. Poo, W. N. Hait, Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I-II study. Cancer Chemother. Pharmacol. 36, 373-378 (1995).
-
(1995)
Cancer Chemother. Pharmacol.
, vol.36
, pp. 373-378
-
-
Buzaid, A.1
Pizzorno, G.2
Marsh, J.C.3
Ravikumar, T.S.4
Murren, J.R.5
Todd, M.6
Strair, R.K.7
Poo, W.-J.8
Hait, W.N.9
-
13
-
-
0026721532
-
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
-
P. Piedbois, M. Buyse, Y. Rustum, D. Machover, C. Erlichman, R. W. Carlson, F. Valone, R. Labianca, J. H. Doroshow, N. Petrelli, Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol. 10, 896-903 (1992).
-
(1992)
J. Clin. Oncol.
, vol.10
, pp. 896-903
-
-
Piedbois, P.1
Buyse, M.2
Rustum, Y.3
Machover, D.4
Erlichman, C.5
Carlson, R.W.6
Valone, F.7
Labianca, R.8
Doroshow, J.H.9
Petrelli, N.10
-
14
-
-
0023187085
-
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile
-
D. Heggie, J.-P. Sommadossi, D. S. Cross, W. J. Huster, R. Diasio, Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res. 47, 2203-2206 (1987).
-
(1987)
Cancer Res.
, vol.47
, pp. 2203-2206
-
-
Heggie, D.1
Sommadossi, J.-P.2
Cross, D.S.3
Huster, W.J.4
Diasio, R.5
-
15
-
-
0026701936
-
Mechanismbased inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil
-
D. J. T. Porter, W. G. Chestnut, B. M. Merrill, T. Spector, Mechanismbased inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J. Biol. Chem. 267, 5236-5242 (1992).
-
(1992)
J. Biol. Chem.
, vol.267
, pp. 5236-5242
-
-
Porter, D.J.T.1
Chestnut, W.G.2
Merrill, B.M.3
Spector, T.4
-
16
-
-
0028281781
-
5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing colorectal carcinoma
-
S. Cao, Y. M. Rustum, T. Spector, 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing colorectal carcinoma. Cancer Res. 54, 1507-1510 (1994).
-
(1994)
Cancer Res.
, vol.54
, pp. 1507-1510
-
-
Cao, S.1
Rustum, Y.M.2
Spector, T.3
-
17
-
-
0020037313
-
5-Benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase
-
J. G. Niedzwicki, S. H. Chu, M. H. el Kouni, E. C. Rowe, S, Cha, 5-Benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase. Biochem. Pharmacol. 31, 1857-1861 (1982).
-
(1982)
Biochem. Pharmacol.
, vol.31
, pp. 1857-1861
-
-
Niedzwicki, J.G.1
Chu, S.H.2
El Kouni, M.H.3
Rowe, E.C.4
Cha, S.5
-
18
-
-
0022379204
-
Tissue specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine
-
J. W. Darnowski, R. E. Handschumacher, Tissue specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine. Cancer Res. 45, 5364-5368 (1985).
-
(1985)
Cancer Res.
, vol.45
, pp. 5364-5368
-
-
Darnowski, J.W.1
Handschumacher, R.E.2
-
19
-
-
0024375273
-
Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine
-
D. S. Martin, R.L Stolfi, R. C. Sawyer, Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother. Pharmacol. 24, 9-14 (1989).
-
(1989)
Cancer Chemother. Pharmacol.
, vol.24
, pp. 9-14
-
-
Martin, D.S.1
Stolfi, R.L.2
Sawyer, R.C.3
-
20
-
-
0020531847
-
Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver
-
A. Monks, O. Ayers. R. L. Cysyk, Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver. Biochem. Pharmacol. 32, 2003-2009 (1983).
-
(1983)
Biochem. Pharmacol.
, vol.32
, pp. 2003-2009
-
-
Monks, A.1
Ayers, O.2
Cysyk, R.L.3
-
21
-
-
0025921621
-
F magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver
-
P. E. Sijens, Y. M. Huang, N. J. Baldwin, T. C. Ng, F magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver. Cancer Res. 51, 1384-1390 (1991).
-
(1991)
Cancer Res.
, vol.51
, pp. 1384-1390
-
-
Sijens, P.E.1
Huang, Y.M.2
Baldwin, N.J.3
Ng, T.C.4
-
22
-
-
0026360179
-
In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using F nuclear magnetic resonance spectroscopy
-
A. El-Tahtawy, W. Wolf, In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using F nuclear magnetic resonance spectroscopy. Cancer Res. 51, 5806-5812 (1991).
-
(1991)
Cancer Res.
, vol.51
, pp. 5806-5812
-
-
El-Tahtawy, A.1
Wolf, W.2
-
23
-
-
0022638354
-
Tissue uridine pools: Evidence in vivo of a concentrative mechanism for uridine uptake
-
J. W. Darnowski, R. E. Handschumacher, Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake. Cancer Res. 46, 3490-3494 (1986).
-
(1986)
Cancer Res.
, vol.46
, pp. 3490-3494
-
-
Darnowski, J.W.1
Handschumacher, R.E.2
-
24
-
-
0025819516
-
19F NMR spectroscopy
-
19F NMR spectroscopy. Magn. Reson. Med. 19, 113-123 (1991).
-
(1991)
Magn. Reson. Med.
, vol.19
, pp. 113-123
-
-
Koutcher, J.A.1
Sawyer, R.C.2
Kornblith, A.B.3
Stolfi, R.L.4
Martin, D.S.5
Devitt, M.L.6
Young, C.W.7
-
25
-
-
0018390860
-
Comparison of liquid-and gas-liquid chromatographic assays of 5-fluorouracil in plasma
-
N. Christophidis, G. Mihaly, M. Vadja, W. Louis, Comparison of liquid-and gas-liquid chromatographic assays of 5-fluorouracil in plasma. Clin. Chem. 25, 83-87 (1979).
-
(1979)
Clin. Chem.
, vol.25
, pp. 83-87
-
-
Christophidis, N.1
Mihaly, G.2
Vadja, M.3
Louis, W.4
-
26
-
-
0024419144
-
Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS
-
P. M. McSheehy, M. J. Prior, J. R. Griffiths, Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS. Br. J. Cancer. 60, 303-309 (1989).
-
(1989)
Br. J. Cancer.
, vol.60
, pp. 303-309
-
-
McSheehy, P.M.1
Prior, M.J.2
Griffiths, J.R.3
-
27
-
-
0025887689
-
Multinuclear MR investigation of the metabolic response of the murine RIF-1 tumor to 5-fluorouracil chemotherapy
-
P. E. Sijens, N. J. Baldwin, T. C. Ng, Multinuclear MR investigation of the metabolic response of the murine RIF-1 tumor to 5-fluorouracil chemotherapy Magn. Reson. Med. 19, 373-385 (1991).
-
(1991)
Magn. Reson. Med.
, vol.19
, pp. 373-385
-
-
Sijens, P.E.1
Baldwin, N.J.2
Ng, T.C.3
-
28
-
-
0026603804
-
Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: A 19F-MRS study in vivo
-
P. M. J. McSheehy, M. J. W. Prior, J.R Griffiths, Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo. Br. J. Cancer 65, 369-375 (1992).
-
(1992)
Br. J. Cancer
, vol.65
, pp. 369-375
-
-
McSheehy, P.M.J.1
Prior, M.J.W.2
Griffiths, J.R.3
-
29
-
-
0027303708
-
19F magnetic resonance spectroscopy in patients with colorectal cancer: A pilot study
-
19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. Ann. Oncol. 4, 597-602 (1993).
-
(1993)
Ann. Oncol.
, vol.4
, pp. 597-602
-
-
Findlay, M.P.N.1
Leach, M.O.2
Cunningham, D.3
Collins, D.J.4
Payne, G.S.5
Glaholm, J.6
Mansi, J.L.7
McCready, V.R.8
-
30
-
-
0023942798
-
Benzylacyclouridine pharmacokinetics, metabolism and biochemical effect in mice
-
J. W. Darnowski, R. E. Handschumacher, Benzylacyclouridine pharmacokinetics, metabolism and biochemical effect in mice. Biochem. Pharmacol. 37, 2613-2819 (1988).
-
(1988)
Biochem. Pharmacol.
, vol.37
, pp. 2613-2819
-
-
Darnowski, J.W.1
Handschumacher, R.E.2
-
31
-
-
0024599491
-
Structure-activity relationship of ligands of dihydrouracil dehydrogenase from mouse liver
-
F. N. M. Naguib, M. H. el Kouni, S. M. Cha, Structure-activity relationship of ligands of dihydrouracil dehydrogenase from mouse liver. Biochem. Pharmacol. 38, 1471-1480 (1989).
-
(1989)
Biochem. Pharmacol.
, vol.38
, pp. 1471-1480
-
-
Naguib, F.N.M.1
El Kouni, M.H.2
Cha, S.M.3
-
32
-
-
0023909330
-
Determinants of tumor blood flow: A review
-
R. K. Jain, Determinants of tumor blood flow: a review. Cancer Res. 48, 2641-2658 (1988).
-
(1988)
Cancer Res.
, vol.48
, pp. 2641-2658
-
-
Jain, R.K.1
-
33
-
-
0001850880
-
Physiological resistance to the treatment of solid tumors
-
(B. A. Teicher, Ed.), M. Dekker, New York
-
R.K Jain, Physiological resistance to the treatment of solid tumors, in "Drug Resistance in Oncology" (B. A. Teicher, Ed.), pp. 87-105, M. Dekker, New York, 1993.
-
(1993)
Drug Resistance in Oncology
, pp. 87-105
-
-
Jain, R.K.1
-
34
-
-
0023481357
-
Transport of molecules across tumor vasculature
-
R. K. Jain, Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6, 559-593 (1987).
-
(1987)
Cancer Metastasis Rev.
, vol.6
, pp. 559-593
-
-
Jain, R.K.1
-
35
-
-
0025043987
-
19F nuclear magnetic resonance spectroscopy pharmacokinetics
-
19F nuclear magnetic resonance spectroscopy pharmacokinetics. J. Clin. Oncol. 8, 1868-1873 (1990).
-
(1990)
J. Clin. Oncol.
, vol.8
, pp. 1868-1873
-
-
Presant, C.A.1
Wolf, W.2
Albright, M.J.3
Servis, K.L.4
Ring, R.I.I.I.5
Atkinson, D.6
Ong, R.L.7
Wiseman, C.8
King, M.9
Blayney, D.10
Kennedy, P.11
El-Tahtawy, A.12
Singh, M.13
Shani, J.14
-
36
-
-
0025096726
-
19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits
-
19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc. Natl. Acad. Sci. USA 87, 492-496 (1990).
-
(1990)
Proc. Natl. Acad. Sci. USA
, vol.87
, pp. 492-496
-
-
Wolf, W.1
Presant, C.A.2
Servis, K.L.3
El-Tahtawy, A.4
Albright, M.J.5
Barker, P.B.6
Ring, R.I.I.I.7
Atkinson, D.8
Ong, R.9
King, M.10
Singh, M.11
Ray, M.12
Wiseman, C.13
Blayney, D.14
Shani, J.15
-
37
-
-
9844229470
-
Pharmacokinetics of benzylacyclouridine (BAU) in patients with refractory solid tumors (phase I trial)
-
G. Pizzorno, J. C. Marsh, J. J. Leffert, R. E. Handschumacher, P. Calabresi, Pharmacokinetics of benzylacyclouridine (BAU) in patients with refractory solid tumors (phase I trial). Proc. Am. Assoc. Cancer Res. 34, 22 (1993).
-
(1993)
Proc. Am. Assoc. Cancer Res.
, vol.34
, pp. 22
-
-
Pizzorno, G.1
Marsh, J.C.2
Leffert, J.J.3
Handschumacher, R.E.4
Calabresi, P.5
|